Ultrasonography-guided core needle biopsy of cervical lymph nodes for diagnosing head and neck lymphoma compared with open surgical biopsy: Exploration for factors that shape diagnostic yield

Kwon, Minsu; Yim, Chaedong; Baek, Hye Jin; Lee, Jong Sil; Seo, Ji‐Hyun; Kim, Jin Pyeong; Woo, Seung Hoon; Park, Jung Je

doi:10.1016/j.amjoto.2018.07.011

Cited by 14 publications

(10 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although not statistically significant in this study, a higher percentage of CNB from deep anatomic sites (9.2%) failed to provide a complete final diagnosis subclassification compared with the CNB from superficial anatomic sites (7.8%). These data are in accordance with previous publications 25,32,38,54…”

Section: Discussionsupporting

confidence: 94%

Core Needle Biopsy in Lymphoma Diagnosis

Gonçalves¹,

Oliveira²,

Sandes

et al. 2022

American Journal of Surgical Pathology

View full text Add to dashboard Cite

To compare the diagnostic accuracy of core needle biopsies (CNBs) and surgical excisional biopsies (SEBs), samples of lymphoid proliferation from a single institution from 2013 to 2017 (N=476) were divided into groups of CNB (N=218) and SEB (N=258). The diagnostic accuracy of these samples was evaluated as a percentage of conclusive diagnosis, according to the World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues. The contribution of clinical data, the assessment of sample adequacy by a pathologist during the procedure, the number and size of fragments, the needle gauge, the ancillary tests, and the type of lymphoid proliferation were also examined. The diagnostic accuracy of SEB was 97.3% and CNB 91.3% (P=0.010). Additional factors considered essential for establishing the final diagnosis in some cases were: clinical information (20.6% CNB, 7.4% SEB; P<0.001); immunohistochemistry (96.3% CNB, 91.5% SEB; P=0.024); flow cytometry (12% CNB, 6.8% SEB; P=0.165); and other complementary tests (8.2% CNB, 17.3% SEB; P=0.058). Factors that did not influence performance were the evaluation of sample adequacy during the procedure, the number and size of fragments, and the needle gauge. Increased percentage of nondiagnostic CNB was observed in T-cell lymphomas (30%), followed by classic Hodgkin lymphoma (10.6%). The main limitation of CNB was the evaluation of morphologically heterogenous diseases. CNB is useful and safe in lymphoma diagnosis provided it is carried out by a team of experienced professionals. Having an interventional radiology team engaged with pathology is an essential component to achieve adequate rates of specific diagnoses in CNB specimens.

show abstract

Section: Discussionsupporting

confidence: 94%

Core Needle Biopsy in Lymphoma Diagnosis

Gonçalves¹,

Oliveira²,

Sandes

et al. 2022

American Journal of Surgical Pathology

View full text Add to dashboard Cite

show abstract

“…The majority of these patients had relapsed lymphoma as PET‐CT in new cases of lymphoma was not generally performed prior to histological confirmation of diagnosis. Where there are several possible targets, PET‐CT imaging is a valuable tool to direct selection and increase the likelihood of confirmatory diagnoses in this setting 13 …”

Section: Discussionmentioning

confidence: 99%

Lymph node core biopsies reliably permit diagnosis of lymphoproliferative diseases. Real‐World Experience from 554 sequential core biopsies from a single centre

Cohen

Brodermann

Dervin

et al. 2020

European J of Haematology

View full text Add to dashboard Cite

Introduction Whilst excision biopsy is traditionally preferred, advances in radiological and histological techniques warrant a re‐look at core biopsy as a viable primary diagnostic method. Method Over a 3‐year period, all patients who underwent core biopsy to investigate lymphoma at our centre were included. Results 554 consecutive patients were included (40.1% prior lymphoma and 59.4% new presentations). Three or more cores were taken in 420 (75.8%) cases. Median time from request to biopsy and biopsy to histology report was 2 (0‐40) days and 7 (1‐24) days, respectively. 510/544 (93.8%) biopsies were diagnostic. There was no difference in whether the biopsy was diagnostic based on indication (new vs. relapsed lymphoma) (P = .445), whether biopsy was PET‐directed (P = .507), for T‐cell lymphoma (P = .468) or nodal vs. extra‐nodal (P = .693). Thirty‐eight patients (6.9%) required a second biopsy due to inadequate tissue. In a patient experience survey, only 13.9% reported any complications (1 self‐limiting minor bleeding, 4 bruising) whilst 16.7% reported any discomfort beyond 12 hours. Conclusion Core biopsy performed by experienced radiologists and analysed by expert haemato‐pathologists is a reliable, well‐tolerated method for diagnosing lymphoma and confirming relapse. Multiple cores can be obtained under local anaesthetic yielding sufficient material in the majority of cases.

show abstract

“…FDG Avidity of the metabolic information obtained from a previous FDG PET/CT scan can have valuable benefits for image guided biopsy (24). A recent study found the mean SUV max of lymph node on PET-CT in confirmatively diagnosed subjects much higher than the deferred counterparts on US-CNB in diagnosing head and neck lymphoma involving cervical nodes (25). Present study selected the deep-site dominant lesion with the maximum SUV for biopsy target, and found that the mean SUV max of the targeted lesion on PET-CT was higher in patients who underwent US-CNB with actionable diagnoses of lymphoma, which imply the lesion with greater SUV should be selected as the target of biopsy.…”

Section: Discussionmentioning

confidence: 99%

Core Needle Biopsy Targeting the Viable Area of Deep-Sited Dominant Lesion Verified by Color Doppler and/or Contrast-Enhanced Ultrasound Contribute to the Actionable Diagnosis of the Patients Suspicious of Lymphoma

Wang

et al. 2020

Front. Oncol.

View full text Add to dashboard Cite

Background: Inadequate accuracy of ultrasound-guided core needle biopsy (US-CNB) urges further improvement for the diagnosis and management of lymphoma to meet with the practitioners' increased reliance on this mini-invasive approach. Methods: Data related to US-CNB of the deep-sited dominant lesions suspicious of lymphoma detected by computer tomography or positron-emission tomography/computer tomography for eligibility assessment of three prospective clinical trials were collected in advance. A retrospective analysis of the prospective data collection was performed, in which Viable-targeting US-CNB that Color Doppler flow imaging (CDFI) and/or contrast enhanced ultrasound (CEUS) were employed to select viable area for biopsy target compared with Routine US-CNB that routine procedure of evaluation and guidance using gray-scale ultrasound with CDFI in terms of the yield of clinically actionable diagnosis and safety, and determinants for the successful US-CNB that established an actionable diagnosis were explored. The establishment of final diagnosis was based on surgical pathology or medical response to therapy with follow-up at least 6 months. Results: A total of 245 patients underwent Routine US-CNB (N = 120) or Viabletargeting US-CNB (N = 125), of which 91 (91/120, 75.8%) and 112 (112/125, 89.6%) were revealed with actionable diagnoses, respectively (p = 0.004, OR 0.846, 95%

show abstract

Ultrasonography-guided core needle biopsy of cervical lymph nodes for diagnosing head and neck lymphoma compared with open surgical biopsy: Exploration for factors that shape diagnostic yield

Cited by 14 publications

References 19 publications

Core Needle Biopsy in Lymphoma Diagnosis

Core Needle Biopsy in Lymphoma Diagnosis

Lymph node core biopsies reliably permit diagnosis of lymphoproliferative diseases. Real‐World Experience from 554 sequential core biopsies from a single centre

Core Needle Biopsy Targeting the Viable Area of Deep-Sited Dominant Lesion Verified by Color Doppler and/or Contrast-Enhanced Ultrasound Contribute to the Actionable Diagnosis of the Patients Suspicious of Lymphoma

Contact Info

Product

Resources

About